Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

June 18-20, 2019
Park Central Hotel,
San Francisco, CA

The next generation proteins conference looking beyond antibodies to transform promising proteins into next generation medicine

Employ the creativity behind protein engineering and design into innovative biologics. Maximize the therapeutic window with fresh perspectives and cutting-edge targets.

Save $400!

Register by April 26 and save $400 off industry rates. Don't Miss out!

Accelerate promising new molecules into differentiated products

Next Generation Bioconjugates
  • Learn about novel conjugation techniques and technology to create a more cost effective, high efficacy, easier process.
  • Tackle bioconjugations beyond antibodies and cytotoxins: What are the next generation delivery vehicles and modalities?
  • Overcome bioconjugate challenges by maximizing your therapeutic window and maintaining stability. 
Creative Engineering & Design
  • See the latest expansion of antibody mimetic molecules and the future of these promising therapeutic proteins in a clinical setting.
  • Uncover creative engineering and design approaches for next generation protein therapeutics: Bi and multi specifics, Bispecific T cell engagers, Non-Antibody Scaffolds, Checkpoint Inhibitors and Peptoids.  
  • Are you up-to-date on the use of novel protein therapeutics for diseases outside of oncology?
Drug Design, Delivery & Patient Welfare
  • Discover how the use of systems and synthetic biology can be used to identify novel targets.
  • Delve into Bispecific design and production to achieve a product with maximum quality.
  • Achieve delivery into cells and across the blood-brain barrier.
  • What do doctors look for in new drugs and how can side effects be reduced?

Unmatched networking opportunities


  • Network and mingle with 20+ CRO's, CMO's, and suppliers that cater exclusively to the biopharma market.

  • Read and discuss more than 25 academic posters highlighting unpublished research and data from top scientists in the industry.

  • Enjoy our evening cocktail reception on Day 1 taking place in the Poster & Exhibit Hall.

  • Eat lunch with top scientists and industry leaders during our 3 Networking Luncheons.

  • Continue the conversation during the numerous morning and afternoon refreshment breaks on each conference day.

The Leading Meeting for Bioconjugates and Next Generation Protein Therapeutics

35+
Case Studies and New Data Presentations
250+
Attendees from Pharmaceutical, Biotech, and Solution Providers
60+
Experts and Scientists presenting new data and case studies

Exclusive Whitepaper Downloads

Use of Next Generation Protein Therapeutics Over Traditional Monoclonal Antibodies and Different Approaches

According to BIS Research and Research and Markets the worldwide biologics drug discovery market is predicted to increase from USD $8.1 billion in 2015 to USD $22.7 billion by 2025 (Figure 1). The biologics discovery growth rate is predicted to be faster than in the dominant small molecule discovery sector. Monoclonal antibodies are expected to make up just under half of the biologics discovery market in 2025. Engineered or recombinant proteins such as next generation protein therapeutics are expected to contribute 3 billion to the market in 2025.

The dominance of monoclonal antibodies (mAbs) are due to several factors including their efficacy brought about by their high specificity allowing selective targeting

Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies

The last decade has seen substantial growth of immunotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.

Sponsorship & Exhibition Opportunities


Showcase the adaptability of your products to leading scientists representing the upstream development and bioprocessing chain, spanning early stage discovery to early stage development.

For more information or to begin building your custom sponsorship package today, contact Kristin Skahan at  (857) 504-6730 or kristin.skahan@knect365.com